349 related articles for article (PubMed ID: 36362287)
1. Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH).
Qi X; Lai J
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362287
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
4. Potential biomarkers in NASH-induced liver cirrhosis with hepatocellular carcinoma: A preliminary work on roles of exosomal miR-182, miR-301a, and miR-373.
Muhammad Yusuf AN; Raja Ali RA; Muhammad Nawawi KN; Mokhtar NM
Malays J Pathol; 2020 Dec; 42(3):377-384. PubMed ID: 33361718
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
8. The role of exosomal miRNA in nonalcoholic fatty liver disease.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
J Cell Physiol; 2022 Apr; 237(4):2078-2094. PubMed ID: 35137416
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
11. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
12. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
[TBL] [Abstract][Full Text] [Related]
13. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.
Wang Y; Liu Z; Zou W; Hong H; Fang H; Tong W
Biomark Med; 2015; 9(11):1189-200. PubMed ID: 26506944
[TBL] [Abstract][Full Text] [Related]
14. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
Ramanathan R; Ali AH; Ibdah JA
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
[TBL] [Abstract][Full Text] [Related]
16. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice.
Rajak S; Tewari A; Raza S; Gupta P; Chakravarti B; Anjum B; Tripathi M; Singh BK; Yen PM; Goel A; Ghosh S; Sinha RA
Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166662. PubMed ID: 36754244
[TBL] [Abstract][Full Text] [Related]
19. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.
Yang L; Hao Y; Boeckmans J; Rodrigues RM; He Y
Pharmacol Ther; 2023 Mar; 243():108353. PubMed ID: 36738973
[TBL] [Abstract][Full Text] [Related]
20. Immune-metabolic interactions in homeostasis and the progression to NASH.
Hoogerland JA; Staels B; Dombrowicz D
Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
